Nurix Therapeutics Enrolls First Patient In Phase 1b/2 Study Of Bexobrutideg Plus Venetoclax In Chronic Lymphocytic Leukemia Under Roche Collaboration
Benzinga Newsdesk 3 weeks ago
News
First patient enrolled in cohort combining bexobrutideg with venetoclaxInitial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLLStrategy includes evaluation of bexobrutideg given in
- First patient enrolled in cohort combining bexobrutideg with venetoclax
- Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL
- Strategy includes evaluation of bexobrutideg given in combination with venetoclax and selected antibodies in the Roche portfolio of B-cell malignancy therapies